Nirma Group Takes 75% Stake In Glenmark Life Sciences
Nirma has acquired a majority stake of 75 per cent in Glenmark Life Sciences from Glenmark Pharmaceuticals about INR 5,651 crore at an enterprise value of ~INR 7,500 crore.
The acquisition will trigger an open offer. Glenmark Life Sciences is engaged in the business of manufacturing and supplying Active Pharmaceutical Ingredients (APIs) to global pharma manufacturers.
The core deal comprised Aashutosh Sampat (Partner), Mehul Shah (Partner), Rohan Shrivastava (Principal Associate), Sagarika Chandel (Senior Associate), Pranita Parakh (Associate) and Shalibhadra Daga (Associate).
Assistance on Securities law aspects Arindam Ghosh (Partner), Shashank Patil (Principal Associate), Gaurang Mansinghka (Associate) and Shubhra Wadhawan (Associate).
Competition Law Aspects - Anisha Chand (Partner), Anshuman Sakle (Partner), Tanveer Verma (Principal Associate) and Rishabh Vora (Associate).
Intellectual Property aspect - Shailendra Bhandare (Partner), Sourav Dan (Principal Associate), Dr. Abdullah Khan (Senior Associate) and Kinjal Parikh (Associate).
Real Estate aspects - Abhiraj Gandhi (Partner) and Nirali Shah (Senior Associate).
Employment Law aspects - Deepak Kumar (Partner), Deeksha Mallik (Senior Associate) and Ransher Singh (Associate).
